- cafead   May 09, 2024 at 07:22: PM
via Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuticals and CRISPR Therapeutics?
It’s not an easy question to answer.
article source
It’s not an easy question to answer.
article source